|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
12608555 |
| 006 |
m d |
| 007 |
cr nn||||mamaa |
| 008 |
200930s2020 si a o 000 0 eng d |
| 005 |
20240709194820.1 |
| 019 |
|
|
|a 1198558852
|a 1202468059
|a 1226202222
|a 1238200331
|a 1238201712
|a 1245000093
|
| 020 |
|
|
|a 9789811575860
|q (electronic bk.)
|
| 020 |
|
|
|a 981157586X
|q (electronic bk.)
|
| 020 |
|
|
|z 9789811575853
|
| 024 |
7 |
|
|a 10.1007/978-981-15-7586-0.
|2 doi
|
| 035 |
|
|
|a (OCoLC)1203181839
|z (OCoLC)1198558852
|z (OCoLC)1202468059
|z (OCoLC)1226202222
|z (OCoLC)1238200331
|z (OCoLC)1238201712
|z (OCoLC)1245000093
|
| 035 |
|
9 |
|a (OCLCCM-CC)1203181839
|
| 040 |
|
|
|a EQF
|b eng
|c EQF
|d OCLCO
|d YDX
|d GW5XE
|d EBLCP
|d N$T
|d OCLCO
|d UKAHL
|d OCLCF
|d S2H
|d OCL
|d OCLCO
|d NLW
|d LIP
|d ERF
|d HS0
|
| 049 |
|
|
|a MAIN
|
| 050 |
|
4 |
|a RC268.4
|
| 072 |
|
7 |
|a MED062000.
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL.
|2 bicssc
|
| 072 |
|
7 |
|a MJCL.
|2 thema
|
| 245 |
0 |
0 |
|a Drug targets in cellular processes of cancer :
|b from nonclinical to preclinical models /
|c Hardeep Singh Tuli, editor.
|
| 264 |
|
1 |
|a Singapore :
|b Springer,
|c 2020.
|
| 300 |
|
|
|a 1 online resource (xiii, 228 p.) :
|b ill. (some col.)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 505 |
0 |
|
|a Chapter 1. History of oncotherapies in cancer biology -- Chapter 2. Electrochemical Sensors and Biosensors for the Detection of Cancer Biomarkers and Drugs -- Chapter 3. Cell cycle arrest: An impending therapeutic strategy to curb cancer -- Chapter 4. Apoptotic cell death: important cellular process as chemotherapeutic target -- Chapter 5. Regulatory roles of autophagy in cancer -- Chapter 6. ROS and Oxidative Stress in Cancer: Recent Advances -- Chapter 7. Inflammatory mediators: Potential drug targets in cancer -- Chapter 8. Pharmacologic modulation of the immune response against tumours in the elderly. Chapter 9. Angiogenesis: A Therapeutic Target for Cancer -- Chapter 10. Metastasis: A major driver of cancer pathogenesis -- Chapter 11. Designing Personalized and Innovative Novel Drug Therapies For Cancer Treatment.
|
| 520 |
|
|
|a This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine. Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.
|
| 650 |
|
0 |
|a Cancer
|x Molecular aspects.
|0 http://id.loc.gov/authorities/subjects/sh89006610
|
| 650 |
|
0 |
|a Drug targeting.
|0 http://id.loc.gov/authorities/subjects/sh88005350
|
| 650 |
|
0 |
|a Cancer
|x Chemotherapy.
|0 http://id.loc.gov/authorities/subjects/sh85019497
|
| 650 |
|
0 |
|a Cancer
|x Research.
|0 http://id.loc.gov/authorities/subjects/sh85019539
|
| 650 |
|
0 |
|a Immunology.
|0 http://id.loc.gov/authorities/subjects/sh85064579
|
| 650 |
|
0 |
|a Cytology.
|0 http://id.loc.gov/authorities/subjects/sh85035240
|
| 650 |
|
7 |
|a Immunology.
|2 bicssc
|
| 650 |
|
7 |
|a Cellular biology (cytology).
|2 bicssc
|
| 650 |
|
7 |
|a Oncology.
|2 bicssc
|
| 650 |
|
7 |
|a Medical
|x Immunology.
|2 bisacsh
|
| 650 |
|
7 |
|a Science
|x Life Sciences
|x Biology
|x Molecular Biology.
|2 bisacsh
|
| 650 |
|
7 |
|a Medical
|x Oncology.
|2 bisacsh
|
| 650 |
|
7 |
|a Drug targeting.
|2 fast
|0 (OCoLC)fst00898709
|
| 650 |
|
7 |
|a Cancer
|x Molecular aspects.
|2 fast
|0 (OCoLC)fst00845397
|
| 650 |
|
7 |
|a Cancer
|x Chemotherapy.
|2 fast
|0 (OCoLC)fst00845327
|
| 650 |
|
7 |
|a Cancer
|x Research.
|2 fast
|0 (OCoLC)fst00845497
|
| 650 |
|
7 |
|a Cytology.
|2 fast
|0 (OCoLC)fst00886282
|
| 650 |
|
7 |
|a Immunology.
|2 fast
|0 (OCoLC)fst00968006
|
| 655 |
|
0 |
|a Electronic books.
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Tuli, Hardeep Singh,
|e editor.
|0 http://id.loc.gov/authorities/names/n2019188877
|
| 776 |
0 |
8 |
|c Original
|z 9811575851
|z 9789811575853
|w (OCoLC)1176324086
|
| 903 |
|
|
|a HeVa
|
| 929 |
|
|
|a oclccm
|
| 999 |
f |
f |
|i 8d8886ad-3e5a-59db-99b7-7a8bad00ffc5
|s 13a76538-1eaa-593a-a5e5-344f1271a033
|
| 928 |
|
|
|t Library of Congress classification
|a RC268.4
|l Online
|c UC-FullText
|u https://link.springer.com/10.1007/978-981-15-7586-0
|z Springer Nature
|g ebooks
|i 12624163
|
